Bleomycin (Blenoxane)

From - A Hematology Oncology Wiki
Jump to: navigation, search

General information

Class/mechanism: Exact mechanism unknown, but suspected to inhibit DNA synthesis, with some evidence inhibition of RNA and protein synthesis. When administered intrapleurally for malignant pleural effusion, bleomycin acts as a sclerosing agent.[1]
Route: IV, IM, SC, intrapleural
Extravasation: irritant or neutral, depending on reference

  • 1 unit of bleomycin = 1 mg of bleomycin

For conciseness and simplicity, currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, Medscape, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]

Diseases for which it is used

Patient drug information

History of changes in FDA indication

  • 7/31/1973: Initial FDA approval

Also known as

  • Brand names: Blenoxane, Bleo, Bleocin, Bleocip, Bleopar, Bleowel


  1. 1.0 1.1 Bleomycin (Blenoxane) package insert (locally hosted backup)
  2. Bleomycin (Blenoxane) patient drug information (Chemocare)
  3. Bleomycin (Blenoxane) patient drug information (UpToDate)